Induction of CXCR3 ligands in murine melanoma model was described to increase the response to the therapy with anti-PD1 antibodies, and elevated CXCR3 levels were observed in plasma of responding melanoma patients [100]. The gene discussed is PDCD1; the disease is melanoma.